Shares in AstraZeneca (AZN) spiked almost 5% in after-market trading amid a report that early-stage human trial data on the drugmaker’s coronavirus vaccine candidate will be disclosed on July 20.The stock rose to $60.60 in Wednesday’s extended trading after earlier jumping 7%. Data results from the Phase 1 trial of the potential coronavirus vaccine, also known as AZD1222, which AstraZeneca is developing with Oxford University, are slated to be published on Monday, according to the Lancet medical journal.The data is expected to demonstrate whether the potential vaccine is safe and whether or not it triggers an immune response. Earlier this …read more
Source:: Yahoo Finance
